Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Risperidone, Olanzapine, Quetiapine Likely to Be Related to Diabetes: AERS DB Analysis
February 9, 2009
- Lack of Information Prevents Use of More Generics
February 9, 2009
- Japan's First Oral Carbapenem Recommended for Approval
February 9, 2009
- REGULATORY NEWS IN BRIEF
February 9, 2009
- Insurance Products to Compensate Subjects in Interventional Studies under Development
February 9, 2009
- R&D NEWS IN BRIEF
February 9, 2009
- Taisho Toyama Aims at Becoming Market Leader for Anti-infection Drugs
February 9, 2009
- Selection of Medical Materials Important for DPC Hospitals: Dr Muto
February 9, 2009
- New Pfizer to Become World's Premier Biopharma Company: CEO Jeff Kindler
February 9, 2009
- PICCs Cut Treatment Costs by Reducing Incidence of Complications
February 9, 2009
- Acquisition of Wyeth Does Not Solve Problems: Datamonitor Report
February 9, 2009
- MEDICAL DEVICE NEWS IN BRIEF
February 9, 2009
- Early Identification of Biomarkers Important in Developing Molecular-Targeted Drugs
February 2, 2009
- REGULATORY NEWS IN BRIEF
February 2, 2009
- Daiichi Sankyo to Apply for Anti-Flu Drug in 2009
February 2, 2009
- Statistics
February 2, 2009
- R&D NEWS IN BRIEF
February 2, 2009
- ARB + Diuretic Combinations from Takeda, Novartis Approved at the Same Time
February 2, 2009
- JGA to Make Proposals to Improve Environment for Use of Generics
February 2, 2009
- NEW PRODUCTS
February 2, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…